Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher

Shares of Eleven Biotherapeutics (EBIO) rose nearly 9% yesterday.

    Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public

    Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public

      Enhance Your Portfolio With These 5 Low Price-to-Book Stocks

      P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

        Pick These 4 Low P/CF Stocks & Sail Through a Volatile Market

        Investment in stocks made on diligent value analysis is usually considered one of the best practices.

          Indrajit Bandyopadhyay headshot

          4 Drug/Biotech Stocks to Buy Ahead of World Health Day

          Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.

            Conatus' Emricasan Fails in Phase II Study, Shares Sink

            Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.

              Pick These 5 Winning Stocks Based on a Favorable P/B Ratio

              P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

                Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease

                Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.

                  Horizon Pharma (HZNP) Down 3.9% Since Earnings Report: Can It Rebound?

                  Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Indrajit Bandyopadhyay headshot

                    Is a Recession in the Cards? 4 Safe Bets for Your Portfolio

                    After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.

                      Protagonist Therapeutics Stalls Ulcerative Colitis Study

                      Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.

                        Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                        Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                          Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug

                          Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                            Regeneron Collaborates With Alnylam to Develop NASH Treatment

                            Regeneron Pharmaceuticals (REGN) enters a collaboration with Alnylam to discover and develop RNAi-based therapies for treatment of NASH.

                              Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

                              Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.

                                Swarup Gupta headshot

                                Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks

                                Industry watchers have grown skeptical about Trump's intermittent pronouncements on this issue.

                                  Heron's Pain Candidate Meets Endpoint in Pivotal Studies

                                  Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.

                                    Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal

                                    Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.

                                      5 Valuable Price-to-Book Stocks to Boost Your Portfolio

                                      P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

                                        Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up

                                        Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.

                                          Is Horizon Pharma Public (HZNP) a Great Stock for Value Investors Right Now?

                                          Horizon Pharma (HZNP) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                                            5 Discounted PEG Stocks for Value Investors

                                            PEG-based investing can turn out to be more rewarding if some other relevant parameters are taken into consideration.

                                              Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up

                                              Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.

                                                Zacks.com highlights: TheStreet, Barclays, Horizon Pharma, Regions Financial and TechTarget

                                                Zacks.com highlights: TheStreet, Barclays, Horizon Pharma, Regions Financial and TechTarget

                                                  Swarup Gupta headshot

                                                  5 Cheap Breakout Stocks for Explosive Returns

                                                  The technique seeks to identify stocks whose prices are fluctuating within a specific band.